Immunic (IMUX) Total Liabilities (2013 - 2026)

Immunic has disclosed Total Liabilities across 14 years of filings, most recently posting $38.5 million for Q1 2026.

• Total Liabilities for Q1 2026 came in at $38.5 million, up 49.25% year-over-year; the trailing twelve-month figure through Mar 2026 was $38.5 million (up 49.25% YoY), and the FY2025 annual result was $30.7 million, up 36.93% from the prior year.
• Total Liabilities came in at $38.5 million for Q1 2026 at Immunic, up from $30.7 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $38.5 million in Q1 2026 to a low of $10.8 million in Q2 2022.
• The 5-year median for Total Liabilities is $22.4 million (2024), against an average of $21.9 million.
• Across the five-year window, Total Liabilities plunged 30.78% in 2022 and soared 80.31% in 2023, its largest moves.
• Immunic's Total Liabilities stood at $14.1 million in 2022, then jumped by 80.31% to $25.4 million in 2023, then dropped by 11.55% to $22.4 million in 2024, then surged by 36.93% to $30.7 million in 2025, then climbed by 25.33% to $38.5 million in 2026.
• The last three Total Liabilities figures came in at $38.5 million (Q1 2026), $30.7 million (Q4 2025), and $30.2 million (Q3 2025), per Business Quant data.